Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C27H27N5O3.3C4H6O4 |
Molecular Weight | 1293.3341 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.COCC(=O)NC\C=C\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1.COCC(=O)NC\C=C\C5=CC=C6N=CN=C(NC7=CC(C)=C(OC8=CN=C(C)C=C8)C=C7)C6=C5
InChI
InChIKey=QCQCPVIRLYJQCG-NZTFDADUSA-N
InChI=1S/2C27H27N5O3.3C4H6O4/c2*1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3;3*5-3(6)1-2-4(7)8/h2*4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32);3*1-2H2,(H,5,6)(H,7,8)/b2*5-4+;;;
Molecular Formula | C4H6O4 |
Molecular Weight | 118.088 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C27H27N5O3 |
Molecular Weight | 469.535 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17285315Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00055926 | https://clinicaltrials.gov/ct2/show/NCT00102895
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00055926 | https://clinicaltrials.gov/ct2/show/NCT00102895
CP 724714 is an orally bioavailable, quinazoline-based, selective small molecule inhibitor of the HER2/erbB2 receptor tyrosine kinase. The compound could have particular potential in the treatment of women with metastatic breast cancer, of which 25-30% over express HER2/erbB2. CP 724714 was in preclinical development with Pfizer.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315 |
32.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4940 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4900 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3660 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2740 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4940 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4900 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3990 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17805538 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7360 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7720 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17805538 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17805538 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
DLT: Hyperbilirubinemia, ALT increased... Dose limiting toxicities: Hyperbilirubinemia (grade 3, 20%) Sources: ALT increased (grade 3, 20%) |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
DLT: thrombocytopenia, Pulmonary embolism... Dose limiting toxicities: thrombocytopenia (grade 3, 6.7%) Sources: Pulmonary embolism (grade 4, 6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | grade 3, 20% DLT |
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Hyperbilirubinemia | grade 3, 20% DLT |
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
thrombocytopenia | grade 3, 6.7% DLT |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Pulmonary embolism | grade 4, 6.7% DLT |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315
In phase I-II clinical trials subjects received CP-724,714 as continuous oral daily doses on 21-day cycles for a predefined maximal duration of 17 cycles (51 weeks). There was no washout between cycles. The starting dose level was 250 mg QD. In subsequent dose cohorts, 250 mg BID, 400 mg BID, and 250 mg TID were evaluated. The maximal tolerated dose was identified as 250 mg TID.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:15:26 GMT 2025
by
admin
on
Mon Mar 31 18:15:26 GMT 2025
|
Record UNII |
D9MYY7U9N1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11981427
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
543681-31-8
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY | |||
|
D9MYY7U9N1
Created by
admin on Mon Mar 31 18:15:26 GMT 2025 , Edited by admin on Mon Mar 31 18:15:26 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |